MADRIGAL PHARMACEUTICALS, INC. Item 8.01 Other Events.
On
All baseline and Week 52 biopsies in MAESTRO-NASH were read independently by two central pathologists (glass slides) for the primary analysis read (see the first chart below, Table 1). Each pathologist's scores showed a similar statistically significant magnitude of response at both doses for both liver biopsy endpoints.
As a supportive analysis, a "consensus read" of digitized biopsy images (see the second chart below, Table 2) was conducted in cases where the two pathologists scores disagreed as to whether the there was a response for either the NASH resolution or fibrosis improvement primary endpoints.
Table 1. Dual Primary Endpoints (52 Weeks) - Primary Analysis
Resmetirom Resmetirom
80 mg 100 mg Placebo
Primary Endpoint (n=316) p-value (n=321) p-value (n=318)
NASH resolution (ballooning 0,
inflammation 0,1) with ?2-point
reduction in NAS and no worsening of
fibrosis 26% <0.0001 30% <0.0001 10%
?1-stage improvement in fibrosis with
no worsening of NAS 24% 0.0002 26% <0.0001 14%
Table 2. Dual Primary Endpoints (52 Weeks) - Consensus Read Supportive Analysis
Resmetirom Resmetirom
80 mg 100 mg Placebo
Primary Endpoint (n=316) p-value (n=321) p-value (n=318)
NASH resolution (ballooning 0,
inflammation 0,1) with ?2-point
reduction in NAS and no worsening of
fibrosis 24% <0.0001 28% <0.0001 8%
?1-stage improvement in fibrosis with
no worsening of NAS 24% <0.0001 26% <0.0001 12%
MAESTRO-NASH is an ongoing blinded Phase 3 clinical trial, and enrolled patients continue on therapy after the Week 52 liver biopsy for up to a total of 54 months to accrue hepatic clinical outcome events including histologic conversion to cirrhosis and hepatic decompensation events.
Forward Looking Statements
This Current Report includes "forward-looking statements" made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, that are based on Madrigal's beliefs and assumptions and on information currently available to it, but are subject to factors beyond its control. Forward-looking statements include: all statements that are not historical facts; statements referenced by forward-looking statement identifiers, including the examples in the paragraph below; and statements or references concerning - the potential efficacy and safety of resmetirom for noncirrhotic NASH patients and cirrhotic NASH patients, possible or assumed future results of operations and expenses, business strategies and plans (including ex-US. Launch/partnering plans), research and development activities, and the timing and results associated with the future development of resmetirom, the timing and completion of projected future clinical milestone events, including enrollment, additional studies, top-line data and open label projections, plans, objectives, timing and support for making for making a Subpart H (Accelerated Approval of New Drugs for Serious or Life-Threatening Illnesses) submission to FDA, projections or objectives for obtaining accelerated or full approval for resmetirom, Madrigal's primary and key secondary study endpoints for resmetirom and the potential for achieving such endpoints and projections, the potential to support an additional indication for resmetirom in patients with well-compensated NASH cirrhosis, optimal dosing levels for resmetirom and projections regarding potential NASH or NAFLD and potential patient benefits with resmetirom, including future NASH resolution, safety, fibrosis treatment, cardiovascular effects, lipid treatment, and/or biomarker effects with resmetirom.
3
--------------------------------------------------------------------------------
Forward-looking statements can be identified by terms such as "accelerate," "achieve," "allow," "anticipates," "appear," "be," "believes," "can," "continue," "could," "demonstrates," "design," "estimates," "expectation," "expects," "forecasts," "future," "goal," "help," "hopeful," "inform," "intended," "intends," "may," "might," "on track," "planned," "planning," "plans," "positions," "potential," "powers," "predicts," "predictive," "projects," "seeks," "should," "will," "will achieve," "will be," "would" or similar expressions and the negatives of those terms.
Forward-looking statements are subject to a number of risks and uncertainties
including, but not limited to: the assumptions underlying the forward-looking
statements; risks of obtaining and maintaining regulatory approvals, including,
but not limited to, potential regulatory delays or rejections; risks associated
with meeting the objectives of Madrigal's clinical studies, including, but not
limited to Madrigal's ability to achieve enrollment objectives concerning
patient numbers (including an adequate safety database), outcomes objectives
and/or timing objectives for Madrigal's studies; any delays or failures in
enrollment, and the occurrence of adverse safety events; risks related to the
effects of resmetirom's mechanism of action; the achievement of enrollment
objectives concerning patient number, safety database and/or timing for
Madrigal's studies; enrollment and trial conclusion uncertainties, generally and
in relation to COVID-19 related measures and individual precautionary measures
that may be implemented or continued for an uncertain period of time; market
demand for and acceptance of our products; the potential inability to raise
sufficient capital to fund ongoing operations as currently planned or to obtain
financings on terms similar to those arranged in the past; the ability to
service indebtedness and otherwise comply with debt covenants; outcomes or
trends from competitive studies; future topline data timing or results; the
risks of achieving potential benefits in studies that includes substantially
more patients, and patients with different disease states, than prior studies;
the timing and outcomes of clinical studies of resmetirom; and the uncertainties
inherent in clinical testing. Undue reliance should not be placed on
forward-looking statements, which speak only as of the date they are made.
Madrigal undertakes no obligation to update any forward-looking statements to
reflect new information, events or circumstances after the date they are made,
or to reflect the occurrence of unanticipated events. Please refer to Madrigal's
submissions filed with the
4
--------------------------------------------------------------------------------
© Edgar Online, source
